Lungpacer Starts AERO-PAS Study of AeroPace System
The post-approval study of the ventilator-weaning device began enrolling its first patient at California Pacific Medical Center in San Francisco.
Updated on Nov. 12, 2026 in Diseases

Lungpacer Medical announced first patient enrollment in the AERO-PAS post-approval study of its AeroPace System, with Sutter Health's California Pacific Medical Center opening as the first site. The prospective, single-arm, multicenter study will enroll up to 120 adults who have been on mechanical ventilation for at least 96 hours and have not weaned.
Why it matters
The study will capture safety and effectiveness data through 30 days in routine clinical practice, extending evidence beyond the randomized RESCUE-3 pivotal trial that supported FDA premarket approval. Results could inform how the device is used for patients who struggle to come off ventilators.
The AERO-PAS study will enroll up to 120 adults who have been on mechanical ventilation for at least 96 hours, building on RESCUE-3 results showing a 43% faster weaning rate. Real-world safety and effectiveness outcomes through 30 days remain unknown until the study generates data.
The players
Lungpacer Medical
Lungpacer Medical is a medical device company headquartered in Exton, Pennsylvania, that develops the AeroPace System for ventilator weaning.
California Pacific Medical Center
California Pacific Medical Center is a San Francisco hospital within the Sutter Health network that opened as the first AERO-PAS study site.
George S. Horng, MD
George S. Horng, MD, is a physician serving as Principal Investigator for the AERO-PAS study at California Pacific Medical Center.
The details
AeroPace is delivered through a catheter placed in a central vein, where it stimulates the phrenic nerves to contract the diaphragm. The system integrates into standard ICU workflows without requiring surgical implantation.
Timeline
November 12, 2026: Lungpacer announced first patient enrollment in AERO-PAS.
2028: Study enrollment completion is anticipated.
Clinical Evidence Context
The study follows the randomized RESCUE-3 trial that supported FDA premarket approval, shifting focus from controlled trial conditions to routine ICU use. It addresses ventilator-induced diaphragm dysfunction, where prolonged ventilation can weaken the diaphragm quickly from disuse.
For patients who remain on ventilators for extended periods, the study tests whether a catheter-based diaphragm stimulation approach can be used within existing ICU workflows. Patients and families should discuss with their care teams whether participation or this therapy is appropriate.
The takeaway
The AERO-PAS study will show whether AeroPace performs in everyday ICU care as it did in controlled trials. Clinicians and patients will watch for the 30-day outcome data.
What happens next
Additional AERO-PAS sites are expected to be activated in the coming months, and study enrollment completion is anticipated in 2028.
Further reading
Explore more on Asthma coverage tied to respiratory care in San Francisco.
More information
Review the AeroPace System prescribing safety information on the Lungpacer Medical website.






